Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment

ITPase Activity Modulates the Severity of Anaemia in HCV-Related Cirrhosis Treated with Ribavirin-Containing Interferon-Free Regimens

“…The polymorphisms rs1127354 and rs7270101 were found to be associated with a haemoglobin reduction at week 4 of treatment in 304 genotype-1 CHC patients receiving PEG-IFN plus RBV, while the minor alleles of each variant protected against a haemoglobin reduction; in particular, a 3 g reduction in haemoglobin levels was a rare occurrence in 22 (2%) patients with a reduction in the ITPA activity of less than 30% and in 45% of 212 with normal enzyme activity [33]. These data were confirmed in other investigations both in HCV-genotype-1 [34,35] and HCV-non-1 genotypes [13,32] as well as in patients receiving PEG-IFN plus RBV and a first-generation protease inhibitor [15,36,37].…”

ITPA Deficiency and Ribavirin Level are Still Predictive of Anaemia in HCV–HIV-Coinfected Patients Receiving Ribavirin Combined with a First-Generation DAA (ANRS HC27 Study)

“…ITPA deficiency remained protective towards anaemia at W8 despite the cumulative haematotoxicity of the first-generation NS3/4A PI BOC combined with RBV. This strongly suggests that ITPA deficiency is still predictive of anaemia even when RBV is combined with DAAs with a poor haematological tolerance as recently reported in an HCV-monoinfected population treated with TLV [28]. Moreover, even though RBV is combined with a second-generation DAA like sofosbuvir with a better haematological tolerance profile, anaemia can still occur in 25% of patients [29].…”

Association between inosine triphosphatase rs1127354 polymorphisms and ribavirin‐induced anaemia and outcome in hepatitis C virus‐infected patients: A meta‐analysis

“…A total of 57 studies were considered potentially eligible for inclusion after reviewing titles and abstracts. Finally, 22 studies 7‐11,13‐29 were subjected to qualitative and quantitative analyses (Figure 1), 18 for haemoglobin decline, 10 for severe anaemia, 10 for RBV dose reduction or discontinuation, 12 for SVR of treatment meta‐analysis, and 4 for the therapy of RBV and DAAs. Eighteen of the 21 studies were included in more than one analysis.…”

“…However, no report on meta‐analysis of ITPA polymorphism and DDAs/RBV was published. Studies from Japan and Spanish only found that ITPA rs1127354 was associated with RBV‐related Hb decline, 8‐11 but no significant differences were found. Few references discussed the effect of rs7170101.…”